faricimab Archives

Health Canada approves Vabysmo® (faricimab) for AMD and DME

by Bioblast Editor | Jun 1, 2022 | Biosimilars updates

Roche announced that Health Canada has approved Vabysmo® (faricimab) for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME). This is the first approved treatment in Canada for wet AMD and DME that targets both...

UK NICE recommends Vabysmo® (faricimab) for AMD and DMO

by Bioblast Editor | May 24, 2022 | Biosimilars updates

The UK’s NICE published final draft guidance recommending Vabysmo® (faricimab) for the treatment of adult patients with wet age-related macular degeneration (AMD) or diabetic macular oedema (DMO).

FDA approves Vabysmo™ (faricimab) for the treatment of people with wet age-related macular degeneration and diabetic macular edema

by Bioblast Editor | Jan 28, 2022 | Biosimilars updates

Genentech announced that the FDA has approved Vabysmo™ (faricimab) for the treatment of people with wet age-related macular degeneration and diabetic macular edema.

Roche releases Ph III results of follow-on faricimab

by Bioblast Editor | Feb 12, 2021 | Biosimilars updates

Roche announced new Ph III data shows faricimab (given at intervals of up to four months) is non-inferior compared to aflibercept (given every two months). This may reduce the treatment burden for patients suffering from diabetic macular edema and neovascular...

Roche releases results of faricimab

by Bioblast Editor | Dec 23, 2020 | Biosimilars updates

Roche announces results for its investigational bispecific antibody faricimab in patients with diabetic macular edema. Roche announced that the candidate was generally well-tolerated with no new safety signals identified. This product is being developed as a...